Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070326 | 0.85 | PKM (0.62) | PKMSMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL26659276 | 0.73 | ALKBH1 (0.59) | CYP1A2CYP2C9CYP2C19TDP1L3MBTL1 | |
| SCHEMBL7472993 | 0.73 | PKM (0.56) | PKMSMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15710244 | 0.72 | PKM (0.54) | PKMSMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27780413 | 0.72 | ALDH1A1 (0.51) | SMN1; SMN2CYP1A2CYP2C9CYP2C19TDP1 | |
| SCHEMBL2197462 | 0.71 | PDE4B (0.73) | SMN1; SMN2L3MBTL1ALDH1A1MEN1NPC1 | |
| Acetic Acid SCHEMBL28685853 | 0.70 | PAX8 (0.51) | SMN1; SMN2TDP1L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL2938583 | 0.69 | MEN1 (0.69) | SMN1; SMN2CYP1A2CYP2C9CYP2C19TDP1 | |
| SCHEMBL1304494 | 0.69 | PKM (0.51) | PKMSMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13607159 | 0.68 | LMNA (0.47) | CYP1A2CYP2C9CYP2C19TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1221544-C | Pyrazole cyclic AMP-specific PDE inhibitors | ICOS CORP (US) | 2005-10-05 | — | — | CN | claimed |
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-12-25 | — | — | US | claimed |
| CN-1434817-A | Pyrazole cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORP (US) | 2003-08-06 | — | — | CN | claimed |
| US-7087634-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-6569885-B1 | Such as 1-(4-bromophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester; side effect reduction; for treatment of central nervous system disorders | ICOS CORPORATION | 2003-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | PKM 1060/4885SMN1; SMN2 1631/4885CYP1A2 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.